Cite
HARVARD Citation
Dummer, R. et al. (n.d.). 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. Journal for immunotherapy of cancer. p. A458. [Online].